Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Status: Recruiting
Location: See all (48) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
• Participants who have provided informed consent for this study
Locations
United States
Arizona
Mayo Clinic Cancer Center-Scottsdale
RECRUITING
Phoenix
California
City of Hope
RECRUITING
Duarte
University of California San Francisco
RECRUITING
San Francisco
Stanford University Medical Center
RECRUITING
Stanford
Florida
Moffitt Cancer Center
RECRUITING
Tampa
Georgia
Emory University
RECRUITING
Atlanta
Illinois
Northwestern University
RECRUITING
Chicago
University of Chicago
RECRUITING
Chicago
Indiana
Indiana University
RECRUITING
Indianapolis
Kansas
Kansas University Medical Center
RECRUITING
Westwood
Massachusetts
Beth Israel Deaconess Medical Center
RECRUITING
Boston
Dana Farber Cancer Institute
RECRUITING
Boston
Massachusetts General Hospital
RECRUITING
Boston
Michigan
Barbara Ann Karmanos Cancer Institute
RECRUITING
Detroit
Minnesota
Mayo Clinic Rochester
RECRUITING
Rochester
Missouri
Washington University School Of Medicine
RECRUITING
St Louis
North Carolina
Levine Cancer Institute
RECRUITING
Charlotte
New Jersey
Hackensack University Medical Center
RECRUITING
Hackensack
Rutgers Cancer Institute of New Jersey
RECRUITING
New Brunswick
New York
Roswell Park Cancer Institute
RECRUITING
Buffalo
Memorial Sloan Kettering Cancer Center
RECRUITING
New York
Mount Sinai Medical Center
RECRUITING
New York
Montefiore Medical Center
RECRUITING
The Bronx
Pennsylvania
University of Pennsylvania
RECRUITING
Philadelphia
University of Pittsburgh Medical Center
RECRUITING
Pittsburgh
Tennessee
Sarah Cannon Research Institute
RECRUITING
Nashville
Texas
MD Anderson Cancer Center
RECRUITING
Houston
Wisconsin
Froedtert Memorial
RECRUITING
Milwaukee
Other Locations
Belgium
UZ Gent
RECRUITING
Ghent
UZ Leuven
RECRUITING
Leuven
China
Peking University Third Hospital
RECRUITING
Beijing
West China Hospital Si Chuan University
RECRUITING
Chengdu
Fujian Medical University Union Hospital
RECRUITING
Fuzhou
First Hospital, Zhejiang University Medical College
RECRUITING
Hangzhou
Jiangsu Province Hospital
RECRUITING
Nanjing
Ruijin Hospital Shanghai Jiao Tong University
RECRUITING
Shanghai
Shanghai Changzheng Hospital
RECRUITING
Shanghai
Shanghai Fourth People s Hospital
RECRUITING
Shanghai
The Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITING
Xi'an
France
CHRU de Lille Hopital Claude Huriez
RECRUITING
Nord
Hopital Saint Louis
RECRUITING
Paris
Israel
Tel Aviv Sourasky Medical Center
RECRUITING
Tel Aviv
Japan
Nagoya City University Hospital
ACTIVE_NOT_RECRUITING
Nagoya
Japanese Red Cross Medical Center
ACTIVE_NOT_RECRUITING
Shibuya City
Netherlands
VU Medisch Centrum
RECRUITING
Amsterdam
University Medical Center Groningen
RECRUITING
Groningen
Spain
Clinica Univ. de Navarra
RECRUITING
Pamplona
Hosp Clinico Univ de Salamanca
RECRUITING
Salamanca
Contact Information
Primary
Study Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Time Frame
Start Date: 2022-03-09
Estimated Completion Date: 2037-10-30
Participants
Target number of participants: 295
Treatments
Experimental: Cilta-cel
Participants who had previously received treatment with cilta-cel in a Company-sponsored clinical study (example, NCT04923893, NCT03758417, NCT04181827, NCT05347485, NCT04133636, and NCT03548207) in the global development program will be enrolled into this study once the individual's participation in the particular interventional study has ended or a study has been terminated. Participants will not receive any treatment in this study and will be followed-up at least once per year on delayed adverse events for up to 15 years after receiving the last dose of cilta-cel.
Related Therapeutic Areas
Sponsors
Leads: Janssen Research & Development, LLC